Effect of rivastigmine versus placebo on manic episode in patients with bipolar disorder

Effect of rivastigmine versus placebo on manic episode in patients with bipolar disorder: a double blind randomized clinical trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT201704289014N161

Enrollment

Registered

2017-05-01

Start date

2017-05-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bipolar disorder. Bipolar affective disorder

Interventions

Intervention 1: Intervention group: Standard treatment plus oral rivastigmine 1.5 mg daily for 24 days. Intervention 2: Control group: Standard treatment plus oral placebo daily for 24 days.

Treatment - Drugs

Intervention group: Standard treatment plus oral rivastigmine 1.5 mg daily for 24 days.

Control group: Standard treatment plus oral placebo daily for 24 days.

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Age of 18 to 65 years; bipolar disorder with manic score above 20. Exclusion criteria: Pregnancy or breastfeeding; sensitivity to lithium or Cholinesterase inhibitors drugs; history of suicide or homicide; using substance in the past 2 weeks; using anticholinergic drugs.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Assessing manic severity. Timepoint: before treatment and 4, 8, 12 and 24 days after treatment. Method of measurement: using Young Mania Rating Scale (YMRS).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Hadi Rezaei

Sina Hospital

rezaeesameti@gmail.com+98 81 3827 4184

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026